<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150694</url>
  </required_header>
  <id_info>
    <org_study_id>HEAP Study</org_study_id>
    <nct_id>NCT02150694</nct_id>
  </id_info>
  <brief_title>Local Haemodynamic Effects of Apelin Agonists and Antagonists in Man in Vivo</brief_title>
  <acronym>HEAP</acronym>
  <official_title>Local Haemodynamic Effects of Apelin Agonists and Antagonists in Man in Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apelins are substances which occur naturally in the body, and have an important role in heart
      disease. They have been shown to make blood vessels dilate, and improve the way the heart
      works.

      The investigators have devised 2 sets of experiments to investigate how the apelins affect
      blood vessels.

      In the first group of experiments,the investigators will give healthy volunteers up to 3
      different apelin substances, and use special research techniques to see how they affect the
      way that blood vessels work in the forearm.

      In the second group of experiments, the apelins will be given along with another form of
      apelin which blocks the effects of apelin in laboratory experiments. The investigators want
      to see if it blocks the effects of apelin in healthy humans.

      The investigators intend to test the hypothesis that:

      Apelin agonists are vasodilators in human resistance vessels, this effect will be blocked by
      an apelin receptor antagonist.

      This study will help us to understand more about how apelins work, and to suggest how they
      might be used to treat heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm blood flow measured by forearm plethysmography in response to infused vasodilators</measure>
    <time_frame>2-3 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hand vein diameter measured by Aellig hand vein technique, in response to study peptides</measure>
    <time_frame>2-3 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Apelin agonist infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Studies to measure change in blood flow in response to apelin agonists (1/10/100nmol) using forearm venous occlusion plethysmography and Aellig hand vein technique.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apelin receptor antagonist infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aellig hand vein technique will be used to investigate the change in vein diameter in response to an apelin blocking agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apelin agonist/antagonist co-infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Forearm blood flow study to measure blood flow by forearm venous occlusion plethysmography following intraarterial infusion of apelin receptor agonists and antagonist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Forearm venous occlusion plethysmography</intervention_name>
    <description>Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.</description>
    <arm_group_label>Apelin agonist infusion</arm_group_label>
    <arm_group_label>Apelin agonist/antagonist co-infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aellig hand vein technique</intervention_name>
    <description>Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.</description>
    <arm_group_label>Apelin agonist infusion</arm_group_label>
    <arm_group_label>Apelin receptor antagonist infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apelin agonist infusion</intervention_name>
    <description>Escalating doses of apelin (1/10/100nmol/min) will be administered.</description>
    <arm_group_label>Apelin agonist infusion</arm_group_label>
    <arm_group_label>Apelin agonist/antagonist co-infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apelin receptor antagonist infusion</intervention_name>
    <description>Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides</description>
    <arm_group_label>Apelin receptor antagonist infusion</arm_group_label>
    <arm_group_label>Apelin agonist/antagonist co-infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 70 years

          -  Non-regular smoking (&lt;5 cigarettes per week)

          -  If female, postmenopausal or on days 2-9 of menstrual cycle

        Exclusion Criteria:

          -  Hypertension (sustained BP &gt;160/100mmHg)

          -  Ischaemic Heart Disease

          -  Renal, respiratory or neurological disease

          -  Diabetes mellitus

          -  BMI &gt;30, BMI &lt;18

          -  Pregnant

          -  Smoker

          -  Use of vasoactive medication or NSAIDS/aspirin within 48 hours of study.

          -  Current involvement in other research studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian B Wilkinson, FRCP DM</last_name>
    <role>Study Director</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony P Davenport, MA PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vascular Research Unit</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Dr Aimee Brame MRCP</investigator_full_name>
    <investigator_title>Research Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

